Antimicrobial Resistance in Finland - Finres 1997-2010 by Gunell, Marianne et al.
Marianne Gunell, Antti Hakanen, Janne Aittoniemi, 
Jaana Kauppila, Kaisu Rantakokko-Jalava,
Anne-Mari Rissanen, Kerttu Saha, Martti Vaara, 
Risto Vuento, Pentti Huovinen, Antti Nissinen
(Editors)
D
is
cu
ss
io
n
 p
ap
er
The Finnish Study Group for Antimicrobial Resistance, FiRe, was established in the 
beginning of the 1990’s, with the purpose of collecting all the antimicrobial susceptibility 
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In this ‘Finres 1997-2010’ –discussion paper we present the development of anti-
microbial resistance of 11 of the clinically most important pathogens, covering all of 
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and tuberculosis are based on other forms of surveillance. In addition, this discussion 
paper includes a review of the history – and future – of FiRe, a brief description of the 
demographics of the participating laboratories, and some words on the architecture of 
the Finres database.
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Foreword 
In your hand is a report collated by the Finnish Study Group for Antimicrobial Resistance (FiRe). It 
comprises antimicrobial resistance data on clinically important bacteria, collected during 14 years. The 
FiRe network was founded in the beginning of the 1990’s, to collect specieswise susceptibility data from 
the Finnish clinical microbiology laboratories. The collection of data started in 1997, a year after all the 
laboratories had adopted the FiRe susceptibility testing standard, which corresponded to the CLSI standard, 
with some minor modifications. From this year onwards, susceptibility data has been collected into yearly 
reports of varying format, which have been distributed to the FiRe members and the partners from the 
pharmaceutical industry. The only previous print version was published in 1999. The FiRe laboratories 
adopted the EUCAST standard in the beginning of 2011, and this was therefore a good time to publish a 
summary of the FiRe-standard years, 1997-2010. This time period was used in the title; however, large-
scale surveillance has been done for many bacteria during a much longer time. To give a better view of 
resistance development, we encouraged authors to also refer to other material. Thus an extensive review, 
comprising very varying timespans, on the susceptibility of the most significant pathogens in Finland, was 
put together. 
 
In this report, the resistance development of 11 of the clinically most important pathogens is presented, as 
well as tuberculosis ans salmonella data based on other surveillance systems. A presentation of the history 
and future of FiRe, and a description of the Finres database are also included. 
 
Globally, the resistance situation has worsened, and the increase of multidrug resistant strains has made 
suscebility testing an important part of succesful and safe patient care. In the future, empirical antimicrobial 
treatment will be guided more and more by a knowledge of the local resistance situation. This report strives 
to respond to this need of knowledge. The situation in Finland is comparable to that in other Nordic 
countries, and good compared to the South and Eastern Europe; but ongoing surveillance and strategic 
planning are the prerequisites for stopping new resistance mechanisms from spreading among clinically 
important pathogens also here in Finland.Here, the voluntary surveillance done by the FiRe-laboratories is 
in a key position. 
 
November 2012, Finland 
 
The Authors 
 
 
 
 
Preface to the English translation 
 
This translation was done as a co-work by a number of the authors. In addition to translating the text, some 
minor corrections and clarifications were added. 
 
October 2013, 
 
The translators 
 
 
 
 
THL — Discussionpaper 43/2013 4 Finres 1997-2010 
 
Abstract 
FiRe. Antimicrobial Resistance in Finland – Finres 1997–2010. National Institute for Health and Welfare 
(THL). Discussionpaper 43/2013. 61 pages. Helsinki, Finland 2013. 
ISBN 978-952-302-062-7 (printed); ISBN 978-952-302-063-4 (online publication) 
 
In this report, we have presented resistance trends for 11 of the most clinically important pathogens 
collected in the Finres database between the years 1997 and 2010. The resistance situation among 
Salmonella spp. and Mycobacterium tuberculosis is also included. In addition, this report includes chapters 
on the history and future of FiRe, and a description of the Finres-database. 
 
Antimicrobial resistance in Streptococcus pneumoniae has increased steadily during the previous 
decade. Macrolide resistance is so common that macrolides cannot be recommended as a first line 
treatment of pneumococcal infections. Although the number of penicillin-non-susceptible (I+R) strains is 
high, the proportion of highly penicillin-resistant strains of S. pneumoniae has remained low. 
β-Lactamase mediated ampicillin resistance in Haemophilus influenzae has remained on a low level, 
and amoxycillin-clavulanate is still effective for the treatment of H. influenzae  infections. 
Moraxella catarrhalis –strains have remained susceptible to amoxycillin-clavulanate, and it is almost 
always susceptible to those per os antimicrobials (macrolides, tetracyclines and trimethoprim-sulfa) that 
can be used as alternatives for beta-lactams. 
Group A streptococci are always penicillin-susceptible, but resistance to other antimicrobials do occur. 
Erythromycin resistance in S. pyogenes has markedly gone down since the 1990’s, whereas clindamycin 
resistance has slightly increased, but is still at a low level. 
A major reason for the increase in antimicrobial resistance in Escherichia coli is the increasing number 
of extended-spectrum beta-lactamase (ESBL) producing strains. The increase of β-lactam and 
fluoroquinolone resistance is worrying. Nitrofurantoin and mecillinam have remained effective against E. 
coli strains and only a few percent of the strains are resistant.  
Despite the increasing trend in ESBL producing Klebsiella pneumoniae strains, cephalosporin, 
fluoroquinolone, aminoglycoside, and carbapenem resistance among Klebsiella spp. has remained low 
during the whole study period and there are no signs of increase. 
Carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter spp. varies, whereas multi-drug 
resistance is a significant clinical problem. Carbapenem resistance in P. aeruginosa is increasing and needs 
to be carefully followed. Bacterial strains resistant to almost all available antimicrobials (PDR) are very 
rare in Finland, and so far MDR/PDR strains have only been detected as single findings or small outbreaks.   
In Finland, the first MRSA hospital epidemics occurred in 1991 and until the mid-90’s around 100 
MRSA cases were detected annually. The number of MRSA cases increased sharply from 1997 to 2004, 
but this increase did not continue from 2005 onwards. The susceptibility to antimicrobials used for 
Staphylococcus aureus infections is good. 
Of the β-lactams, only ampicillin, piperacillin and carbapenems are effective against Enterococcus spp. 
Enterococcus faecalis is almost always susceptible to these antimicrobials, whereas over 80 % of clinical 
Enterococcus faecium isolates are ampicillin resistant. Due to β-lactam resistance, vancomycin is the most 
important antimicrobial for the treatment of severe E. faecium infections. The first Finnsih vancomycin-
resistant E. faecium strains were discovered in 1992. The highest percentage (15 %) of vancomycin-
resistant E. faecium was detected in 1997 (mainly due to a local outbreak) and thereafter vancomycin 
resistance has risen over 1 % only in 2000. 
The first ciprofloxacin-resistant Neisseria gonorrhoeae strains in Finland were discovered in 1995 and 
ten years later the percentage of fluoroquinolone resistance was already over 50 %. Ceftriaxone however, is 
still clinically effective against N. gonorrhoeae infections. So far all clinical samples have been 
ceftriaxone-susceptible in Finland, but strains more resistant than the wild-type have started to appear. 
The proportion of highly ciprofloxacin-resistant (MIC ≥ 4 mg/l) Salmonella enterica strains have 
remained low (0–3 %) but the proportion of strains with reduced susceptibility (MIC ≥ 0.125 mg/l) has 
markedly increased among both domestic and foreign Salmonella isolates. The reduced fluoroquinolone 
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susceptibility has increased mostly among strains acquired from Southeast Asia. This is worrisome since 
these reduced fluoroquinolone-susceptible isolates often also are ESBL-producers, making the treatment of 
severe Salmonella infections even more challenging. 
The antimicrobial susceptibility of Mycobacterium tuberculosis strains isolated in Finland has 
remained good. The majority of MDR strains are isolated from patients with a foreign background, which 
reflects the increasing immigration from countries with a high incidence of tuberculosis. Resistance to 
second line tuberculosis antimicrobials is rare, and XDR strains which are resistant to nearly all 
tuberculosis antimicrobials have not yet been detected in Finland. 
 
Keywords: FiRe, Finres, antimicrobial resistance, reduced susceptibility, bacteria  
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1 The FiRe story 
Scientists have warned of antimicrobial resistant bacteria almost as long as antimicrobials have been in use. 
In Finland, antimicrobial susceptibility of bacterial isolates has been tested with the disc diffusion method 
since the 1960’s, when the first laboratory method for routine susceptibility testing was published (1). In 
the 1970’s and 1980’s the first long-term susceptibility test results were collected and published at least in 
Turku and Helsinki. At the same time the first signs of antimicrobial resistance with clinical importance 
were discovered. 
The first comparable study performed simultaneously in several geographical areas was the 
antimicrobial susceptibility study of otitis and tonsillitis pathogens, which was started in 1987 in KTL (The 
National Public Health Institute). In addition to being the basis of the thesis of hospital microbiologist Antti 
Nissinen, this study was the start of the studies on macrolide resistance in Group A streptococcus 
(Streptococcus pyogenes). During the collection of these Group A streptococcal isolates, Helinä Järvinen, a 
specialist in KTL in Turku, noticed the much higher resistance levels in Kaarina and Pöytyä (Turku district) 
compared to other areas (2). At a research group meeting in 1989, it was decided to expand the surveillance 
of erythromycin resistance in Group A streptococci to cover the whole of Finland, and therefore all clinical 
microbiology laboratories in Finland were invited to participate (3,4). 
The first official FiRe (Finnish Study Group for Antimicrobial Susceptibility Testing) meeting was held 
in 1992 in Helsinki. Practically all Finnish clinical microbiology laboratories which perform antimicrobial 
susceptibility testing have participated in the FiRe network since the beginning (5). After the first meeting, 
FiRe has gathered together regularly twice a year, for an annual meeting and educational workshops on 
current topics on susceptibility testing and resistance surveillance. Participation in these meetings has 
always been abundant. 
 
 
FiRe’s 10th Anniversary meeting 
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Pentti Huovinen, the chair 
 
 
The FiRe group in 2011 
 
Administration  
The first FiRe meeting set up a board to take care of FiRe’s functions and chief physician Pentti Huovinen 
(KTL) was elected as chair. Hospital microbiologist Antti Nissinen (KSKS) was elected as secretary and 
coordinator. The other members of the first FiRe board were associate chief physician Marja-Leena Katila 
(KYS), specialist Heikki Hiekkaniemi (PKKS) and chief physician Martti Vaara (HYKS –laboratory 
diagnostics). This board was elected twice again and was in duty for ten years. In 2002, Martti Vaara was 
elected as chair and new members for the board were chief physician Henrik Jägerroos (LKS), specialist 
Ulla Kärkkäinen (KYS) and associate chief physician Risto Vuento (TAYKS). Heikki Kaukoranta and 
Antti Nissinen continued on the board, Antti Nissinen also as a coordinator. From the beginning the goal 
has been that the board should have representatives from all over the country, both from small and large 
FiRe-laboratories, as well as from the National Public Health Institute (KTL). Between 2005 and 2008 the 
chair of the board was chief physician Risto Vuento and board members were Antti Nissinen, Henrik 
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Jägerroos, Ulla Kärkkäinen and chief microbiologist Pauliina Kärpänoja (PHKS), hospital microbiologist 
Eveliina Tarkka (HUSLAB) and Jaana Vuopio-Varkila (KTL) as the new members. 
In 2007, chief physician Antti Hakanen (KTL) became the coordinator, and since 2008 Antti Nissinen 
has been the chair of the FiRe board. Between 2008 and 2011 the board members were Henrik Jägerroos, 
Antti Hakanen, Ulla Kärkkäinen, Eveliina Tarkka, Risto Vuento and as new members, specialist Jaana 
Kauppila (OYS) and hospital microbiologist Päivi Suomala (MKS). Since 2011, in addition to the chair and 
coordinator, the members of the board have been specialist Janne Aittoniemi (Fimlab), Jaana Kauppila, 
specialist Kaisu Rantakokko-Jalava (TYKSLAB), specialist Anne-Mari Rissanen (ISLAB/KYS), hospital 
microbiologist Kerttu Saha (SeKS) and Martti Vaara. Since 2011 there has also been a secretary on the 
board, first senior researcher Miika Bergman (THL) and in 2012 senior researcher Marianne Gunell (THL). 
Since the beginning, the FiRe laboratory network has been “served” by the Antimicrobial Resistance 
Laboratory (KTL), from 2009 named the Antimicrobial Resistance Unit (THL). The FiRe network gather 
together for an annual meeting and educational workshops twice a year, and new board is elected every 
third year. 
Table 1.1: The FiRe administration 
Chairmen:  City Years 
Pentti Huovinen Turku 1992–2002 
Martti Vaara Helsinki 2002–2005 
Risto Vuento Tampere 2005–2008 
Antti Nissinen Jyväskylä 2008– 
FiRe-coordinators:     
Antti Nissinen Jyväskylä 1992–2007 
Antti Hakanen Turku 2007– 
FiRe -secretary:     
Miika Bergman Turku 2011 
Marianne Gunell Turku 2012 
 
Partners in cooperation – the financial basis of FiRe 
During the years, FiRe has had 17 different pharmaceutical companies as partners in cooperation. With 
these companies FiRe has negotiated a cooperation contract, which has covered the costs of organizing 
meetings for a couple of years at a time. At the moment FiRe has cooperation contracts (via THL) with 
three pharmaceutical companies (Astellas Pharma, Orion Pharma and Pfizer). The cooperation contract has 
given the companies access to an annually published resistance map of the clinically most important 
bacterial isolates in Finland. This resistance map was called ‘Finres’, which is a descriptive and easily 
understood name both in Finland and abroad. It later got its own web site, www.finres.fi, which now also is 
the official FiRe web page. Between 2009 and 2012 FiRe has also got development project money from the 
Ministry of Social and Affairs and Health (STM) Appropriation for Surveillance of Infectious Diseases. 
The FiRe laboratories, however, have not received any extra funding for their surveillance activities. 
 
The FiRe web page 
FiRe has its own web page, www.finres.fi, for internal and external use. It contains information on current 
topics such as meetings and updates to standards. The most essential content are the guidelines on methods 
and interpretations for the use of laboratories, and the latest Finres-results. There is also a link to the 
extranet pages, available only to the FiRe network: they contain presentations from the meetings, and the 
Finres database tool. The www.finres.fi pages are on the THL web domain, and are updated by the 
Antimicrobial Resistance Unit (THL). 
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The harmonizing of breakpoints and the Finres–report  
Collating a national antimicrobial resistance map based on routine material from the clinical laboratories 
was – in retrospect – a brilliant idea. The brilliance of this lay in the idea that the data was collected without 
any special clauses, so that every FiRe laboratory could participate straight from the beginning. To our 
knowledge this is unique: routine data from clinical laboratories are still not collected in any other country. 
The reason behind this is probably the mistrust of the quality of antimicrobial susceptibility testing. FiRe 
was aware of this weakness, but ensuring the quality and comparability of the results from each laboratory 
would have been such a massive and ungratifying work that we would still be in the starting blocks. While 
collecting the data as it was, we produced a map where every laboratory could compare their own data to 
others. Being part of this network in itself encourages laboratories to improve the quality of their own 
susceptibility results. In addition, when comparing one’s results to others, deviations that might be caused 
by flawed methodology could be spotted; this would not have been possible without the pooled national 
data. In 1997, the first Finres-report was put together, after the nationwide adoption of a common 
susceptibility standard, which was completed the year before.  This standard was based on the US CLSI 
(former NCCLS) standard. 
At first, Finres was compiled by hand by Katrina Lager (KTL, Turku). During the 1990’s, the FiRe 
laboratories gradually started to use WHONET, which is a free computer software provided by WHO, to 
collect and analyze their antimicrobial resistance results. This enabled FiRe to produce Excel-based reports: 
this method was used in 2005 and 2006. The mainly handmade Finres-report became history when the 
Finres data management project started in 2008, and the Finres database was created. This database and 
analysing tool was made by senior designer Piia Peltola (KTL, Helsinki), who worked under the 
supervision of data administration manager Jaason Haapakoski, and this project was financed by FiRe. The 
Finres database was used during 2007-2011. In 2012, the Finres2 database project started. The aim of this 
project is to get automated and better analyzing and reporting tools. This project is financed by an 
Infectious Diseases Surveillance grant from the Ministry of Social Affairs and Health. 
Although the most important task of the FiRe-network is to produce resistance surveillance data for 
clinicians, the Finres material has also been used in nine doctoral theses (Table 1.2) and about 30 scientific 
publications (Appendix 1). In addition to antimicrobial susceptibility testing, the link between antimicrobial 
consumption and resistance has been studied (6, 7, 8, 9).  
Table 1.2: Doctoral theses which are based on or have used Finres material 
Year Author University Title of thesis 
1994 Tuula Arstila Turku Beta-lactam resistance among Escherichia coli and Klebsiella species.  
1994 Helena Seppälä Turku Streptococcus pyogenes; erythromycin resistance and molecular typing. 
1995 Antti Nissinen Helsinki Antimicrobial resistance of four major respiratory bacterial pathogens, 
Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus 
influenzae, and Moraxella catarrhalis.  
1996 Tiina Leistevuo Turku Antimicrobial agents in the elderly: resistance of fecal aerobic gram-negative 
bacilli in the geriatric hospital and the community.  
1998 Raija Manninen Turku Determination of antimicrobial resistance in five major clinical bacterial 
pathogens.  
2000 Janne Kataja Turku Molecular epidemiology and resistance genes of macrolide-resistant beta-
hemolytic streptococci.  
2002 Marja Pihlajamäki Turku Antimicrobial resistance in Streptococcus pneumoniae, with special reference 
to macrolide resistance. 
2009 Merja Rantala Helsinki Antimicrobial resistance in Streptococcus pneumoniae in Finland with special 
reference to macrolides and telithromycin. 
2009 Sofia Forssten Turku Genetic basis and diagnostics of extended-spectrum beta-lactamases among 
Enterobacteriaceae in Finland. 
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The EUCAST-standard and the future of FiRe 
Since the beginning of 2011, all FiRe laboratories use the common European EUCAST susceptibility 
testing standard. At the moment of writing, Finland was the only country in Europe where all laboratories 
used the EUCAST-standard, according to an international quality control questionnaire. The reason for the 
change of standard was the perception that EUCAST is a more up to date and more frequently updated 
standard than CLSI. The transition was facilitated by the unanimous decision by the FiRe group, and the 
long common history of harmonizing susceptibility testing methods. EUCAST is a project which is 
commonly financed by the European Centre for Disease Prevention and Control (ECDC) and the European 
Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the aim of EUCAST is to 
maintain the antimicrobial susceptibility testing standard as well as being a networking body for National 
Antimicrobial Susceptibility Testing Committees (NACs). FiRe is the official NAC of Finland. 
Discussions and aiming for common goals have been peculiar to FiRe. Therefore it is not a surprise that 
the FiRe-meetings have been so popular during these 20 years. At these meetings, not only the findings of 
the Finres-report or current resistance issues are discussed, but also quality and comparability issues of 
susceptibility testing. After every meeting, the participants return home, having learned new things and 
being ever more convinced about the importance of this collaboration. It is a good basis to build on during 
the following years and decades. 
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2 Defining the Finres data 
2.1 The FiRe network 
Right from the start, all Finnish clinical microbiology laboratories that perform susceptibility testing have 
been active in the network. At present FiRe is comprised of 24 laboratories (Table 2.1) and the 
bacteriological units of the National Institute for Health and Welfare. At most there have been  27 FiRe-
laboratories, but as a result of fusions (Jorv hospital was merged with HUS in 2006, Medix PLC and 
Yhtyneet laboratories PLC were merged into Yhtyneet Medix Laboratories PLC in 2010) and other 
changes (Oulun Diakonissalaitos stopped doing susceptibility testing) the number was 24 in 2010. The 
majority are laboratories serving central hospitals (15) and university hospitals (5). In addition to these, also 
one university laboratory (Turku University) and three private laboratories are members. The 20 central and 
university hospital laboratories, who do blood cultures, have also participated in the ECDC-coordinated 
resistance surveillance programme (European Antimicrobial Resistance Surveillance Network – EARS-Net) 
from the start in 2010. Before this, 17 FiRe-laboratories took part in the EU-financed programme preceding 
this (European Antimicrobial Resistance Surveillance System – EARSS), which was coordinated by the 
Dutch National Institute for Public Health and the Environment (RIVM) during the years 1999-2009. 
Table 2.1: The FiRe-laboratories in 2010 
FiRe-laboratory City Hospital district 
HUSLAB Helsinki Helsinki and Uusimaa  
Fimlab Tampere Pirkanmaa 
TYKSLAB Turku Varsinais-Suomi 
OYSLAB Oulu Pohjois-Pohjanmaa 
KESLAB/ Central Finland Central Hospital Jyväskylä Keski-Suomi 
ISLAB/KYS Kuopio Pohjois-Savo 
SataDiag/ Satakunta Central Hospital Pori Satakunta 
Päijät-Häme Social and Health Group   Lahti Päijät-Häme 
Seinäjoki Central Hospital Seinäjoki Etelä-Pohjanmaa 
Carea/ Kymenlaakso Central Hospital Kotka Kymenlaakso 
Kanta-Häme Central Hospital Hämeenlinna Kanta-Häme 
Vaasa Central Hospital Vaasa Vaasa 
ISLAB/ Pohjois-Karjala Central Hospital Joensuu Pohjois-Karjala 
Eksote/ Etelä-Karjala Central Hospital Lappeenranta Etelä-Karjala 
Lappi Central Hospital Rovaniemi Lappi 
ISLAB/ Mikkeli Central Hospital Mikkeli Etelä-Savo 
Keski-Pohjanmaa Central Hospital Kokkola Keski-Pohjanmaa 
Länsi-Pohja Central Hospital Kemi Länsi-Pohja 
ISLAB/Savonlinna Central Hospital Savonlinna Itä-Savo 
Kainuu Central Hospital Kajaani Kainuu 
Yhtyneet Medix Laboratoriot PLC* Espoo   
UTULab, Turku University * Turku   
Vita-terveyspalvelut PLC* Helsinki   
General practice  Pulssi/ Terveystalo * Turku   
*Do not participate in the EARS-Net surveillance. 
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2.1.1 Denominator data for the FiRe-laboratories 
So far, the FiRe-network has not regularly collected data which could be used to eg. calculate resistance 
prevalence in relation to population size. However, already EARSS, and its successor EARS-Net have 
collected such data yearly from the participating laboratories. This data tells the coverage of each 
laboratory, if the laboratory serves one or several hospitals, and the number of blood cultures per year. 
Table 2.2 presents the data collected for 2010 (or 2011 if the numbers for 2010 were not available). 
Table 2.2: Denominator data for the FiRe-laboratories 
Clinical microbiology laboratory Geographical area to serve Population 
coverage 
Total number 
of laboratory 
samples/year 
Total 
number 
of blood 
cultures
/year 
HUSLAB Helsinki and Uusimaa hospital 
district 
1 500 000 1 160 000 91 000 
Fimlab Pirkanmaa hospital district 489 000 477 600 33 381 
TYKSLAB Varsinais-Suomi hospital district 470 000 187 000 25 419 
OYSLAB Pohjois-Pohjanmaa  hospital district 400 000 114 000 28 500 
KESLAB/ Central Finland Central 
Hospital 
Keski-Suomi hospital district 273 000 130 251 15 085 
ISLAB/ KYS Pohjois-Savo hospital district 248 000 217 855 20 277 
SataDiag/ Satakunta Central Hospital Satakunta hospital district 225 000 128 495 14 844 
Päijät-Häme Social and Health Group   Päijät-Häme hospital district 210 000 127 334 10 000 
Seinäjoki Central Hospital Etelä-Pohjanmaa hospital district 198 671 106 171 8 868 
Carea/ Kymenlaakso Central Hospital Kymenlaakso s hospital district 175 000 111 107 11 242 
Kanta-Häme Central Hospital Kanta-Häme hospital district 170 000 71 000 11 500 
Vaasa Central Hospital Vaasan hospital district 166 500 100 000 5 600 
ISLAB/ Pohjois-Karjala Central 
Hospital 
Pohjois-Karjala hospital district 160 000 110 000 9 500 
Eksote/ Etelä-Karjala Central Hospital Etelä-Karjala social and health 
district and Imatra city 
130 000 100 353 9585 
Lappi Central Hospital Lappi s hospital district 118 000 77 443 9 955 
ISLAB/ Mikkeli Central Hospital Etelä-Savo hospital district 105 952 46 141 6 090 
Keski-Pohjanmaa Central Hospital Keski-Pohjanmaa  hospital district 100 000 50 600 5 389 
Kainuu Central Hospital Kainuu region 78 000 48 900 5 000 
Länsi-Pohja  Central Hospital Länsi-Pohja hospital district 65 000 26 361 4 636 
ISLAB/ Savonlinna Central Hospital Itä-Savon hospital district 45 000 15 902 3 437 
Yhtyneet Medix Laboratoriot  PLC Whole Finland   128 500 - 
UTULab, Turku University Whole Finland, inc.  Åland   120 000 - 
Vita-terveyspalvelut PLC Whole Finland   72 000 - 
General practice  Pulssi/ Terveystalo       - 
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2.2 Antimicrobial susceptibility testing 
Antimicrobials either kill the microbe, or hinder its growth. All antimicrobials are not effective against all 
bacteria at the concentrations that can be achieved clinically. If all, or almost all, strains of a certain species 
are resistant to an antimicrobial, the species is intrinsically resistant. If the species usually is susceptible, 
but some strains develop resistance, they have acquired resistance. This can be measured in several ways. 
Phenotypic methods are used to see if the bacteria can grow in the presence of the antimicrobial. 
 
In 1996, FiRe decided to introduce harmonised national breakpoints, based on the CLSI (then NCCLS) 
breakpoints, published in the USA. The CLSI standard was translated into Finnish, with some minor 
changes to suit local needs. This translation was named the FiRe-standard for domestic use – in 
international contexts the name CLSI was used. It was in use 1997-2010. It was updated in concert with the 
CLSI standard, with 1-2-year intervals. At the time, the CLSI standard was the best defined and updated 
standard available; it is still widely used also in Europe. In 2010, the European EUCAST standard was 
introduced, and by joint decision this was adopted by the FiRe-laboratories in the beginning of 2011.  
 
The susceptibility testing standard defines the testing conditions to be used (growth medium, antibiotic 
concentrations of disks, the density of the bacterial suspension to be applied, incubation time and 
atmosphere), and the breakpoints used to interpret a strain as susceptible or resistant. The breakpoints are 
species-, antibiotic- and method-specific, and are published as tables. The tables of the FiRe-standard can 
be found on the FiRe webpages (www.finres.fi). The EUCAST tables are freely available at the EUCAST 
homepage (www.eucast.org).  
 
To set the breakpoints, EUCAST considers all of the following: 
1. In what form the antimicrobial is administered. 
2. The most common dosages. 
3. Clinical indications and target organisms. 
4. Species-specific distributions of susceptibility testing results, to determine the epidemiological cut-
off (“ECOFF”) between resistant isolates and those without acquired resistance.  
5. Pharmacokinetics and –dynamics 
6. Information from modelling processes (eg. Monte Carlo simulations to assess the likelihood of 
achieving pharmacodynamic targets). 
7. Outcome of treatment. 
8. Ensuring that known resistance mechanisms are found. 
 
Based on these facts, bacterial isolates are divided into resistant (R), intermediate (I), and susceptible (S). 
 
2.2.1 The disk diffusion method 
In disk diffusion, a bacterial suspension is spread evenly over the 
surface of an agar plate. The density most often used is McFarland 0.5, 
which is a turbidity standard roughly corresponding to 108 bacteria/mL 
in a 0.9 % NaCl solution. Filter paper disks containing the 
antimicrobials to be tested are placed on the plate. The antibiotic 
diffusing from the disk forms a gradient, which stabilize in a couple of 
hours. For some antibiotics, this method does not work; the antibiotic 
does not dissolve sufficiently into the agar, or diffuses too slowly 
because of a large molecular mass. In these cases, other methods have 
to be used. The plates are placed in an incubator, the bacteria multiply, 
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and gradually the growth becomes visible. The bacteria are usually unable to grow in the antibiotic-
containing area close to the disk. This inhibition zone is inversely correlated to the smallest concentration 
of antibiotic that inhibits growth (or the MIC value, see below). 
The disks used by FiRe and EUCAST are 6 mm in diameter, and a maximum of six disks can be placed on 
a standard 90 mm agar plate. After the incubation (usually 18±2 h, 35±2°C), the diameter of the inhibition 
zone is measured (in millimetres), and compared to the breakpoint table.  
The perhaps most critical step in disk diffusion is the determination of the edge of the zone: exactly where 
does the growth stop? Usually the result is clear, but occasionally the edge is fuzzy, or there are separate 
colonies within the inhibition zone. In these cases, harmonised rules of interpretation are especially 
important. EUCAST has published a reading guide covering the most common cases (www.eucast.org). 
 
2.2.2 MIC methods 
The smallest concentration of antibiotic that inhibits growth, or minimum 
inhibitory concentration (MIC) can be determined by exposing the bacteria to 
stepwise increases in antibiotic concentration. After an overnight incubation 
(18±2 h), the MIC is read as the lowest concentration of antibiotic where the 
bacteria are unable to grow. 
 
The agar dilution method 
A series of agar plates are made, where the antibiotic is added to the agar, and the concentration halves for 
each batch (eg. 64-32-16-8-4-2-1 mg/L). Bacterial suspensions are made similarly to the disk diffusion 
method. For each isolate, one drop (1-3 µL) is transferred to each plate in the series, and the plates are 
incubated overnight. This method is useful for studying many isolates at a time; 30-96 isolates can be fitted 
into one series (depending on inoculator and plate size). 
 
The broth dilution method 
A series of dilutions of the antibiotic is made, using the same 
principle as in agar dilution, but broth is used instead of agar. 
Previously, test tubes were used (“macrodilution”), but nowadays 
microtiterplates are used (microdilution). One isolate is inoculated 
per well series.  This method is the ISO-standardised reference 
method (“gold standard”) of antimicrobial susceptibility testing 
(ISO 20776). 
 
The gradient strip method (eg. Etest) 
There are commercial tests using paper or plastic strips, to which an 
antibiotic has been applied in such a way, that a gradient forms in the agar, 
when it is placed on a plate. The strips have printed MIC scales. The MIC 
is read at the intersection of the edge of the inhibition zone and the strip.  
The gradient strip method works well, if the manufacturer has been able 
to calibrate the strip against the reference method for all concentrations. If 
no strains with the highest values were available when the calibration was 
done, results at the upper end of the strip can diverge significantly from 
the reference method. Even though the strip tests are based on agar 
diffusion, similarly to the disk diffusion method, the gradient on the strip largely bypasses the diffusion 
problems encountered in disk testing for some antibiotics. 
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Automated methods 
Automated systems for identification and susceptibility testing have become common in clinical 
microbiology laboratories during the 2000’s. Some systems use the microdilution principle, and these 
correspond most closely to the reference method. To save costs, the dilution series can sometimes be very 
short, which eg. can cause low-level resistence to go undetected, if the lowest concentration is too high. 
Other systems measure the growth dynamics of the isolates in the presence and absence of antibiotics, and 
calculate the MIC. Longer MIC series are possible, since the system can extrapolate between measurement 
points. This method, and its results, deviates more from the reference system. 
 
2.3 The collection of Finres-material 
2.3.1 Clinical samples and bacteria 
The FiRe laboratories analyse the greater part of all clinical microbiology samples in Finland. These 
isolates comprise the Finres database. Bacteria that are tested only at local secondary hospitals, health care 
centres and general practice clinics are not included. Most of these are from urinary tract infections. 
This does not have any remarkable effect on geographical or infection type variation in Finres-database. All 
laboratories perform sample type -specific cultures, using the Association of Finnish Local and Regional 
Authorities nomenclature. Clinically important bacterial findings are identified to species level, and when 
indicated, standard antimicrobial susceptibility testing (see chapter 2.2) is performed. 
 
2.3.2 Antimicrobial susceptibility results 
Antimicrobial susceptibility test results, the diameter of the inhibition zone (mm) or MIC-result (mg/l) is 
entered into the laboratory information system (LIS; e.g. Effica Mikrobiologia, SAMBA) as a feature of the 
bacterial finding. In some laboratories, the diameter of the inhibition zone is not measured if the diameter is 
so large/small that it can safely be directly interpreted as S/R. In that case, the result is only S or R, not the 
numerical value. This method is also used for parallel findings (blood culture). If the susceptibility testing 
is performed with an automated method (for example Vitek 2), MIC-values are automatically transferred to 
the LIS. Results from disc diffusion and E-tests are read and entered manually. The interpretation of 
susceptibility test results (S=susceptible, I=intermediately resistant, R=resistant), which are reported to the 
nursing unit, is based on the standard used (see chapter 2.2). 
 
2.3.3 Resistance data files – the Finres-database 
The FiRe laboratories convert their data from the laboratory database into a WHONET-compatible dBASE 
file, containing all clinically interesting bacterial strains and their antimicrobial susceptibility results (only 
results, not interpretations are included) and patient and sample information. The free WHONET software 
(www.whonet.org), designed for analysis of bacterial resistance, is in use in every FiRe laboratory. From 
this data file, the laboratories extract the subset of results that are included in the Finres database, and 
patient identifications are encrypted. These either monthly or annually collected files are exported to the 
Finres data system (Figure 2.1.) The data system combines the data files into a single national database file. 
Antimicrobial susceptibility results are transferred into the Finres database in the same form as they are in 
the WHONET file. 
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2.3.4 The Finres-report 
According to international tradition (1) only the first bacterial isolate per patient of a certain sample type 
within a certain time scale (usually one year) are included in the Finres–report. FiRe laboratories use 
various methods for encrypting patient’s identifier data, i.e. the encrypted identifier from a certain patient 
can be different if entered from different laboratories. Therefore it has been agreed that the first finding per 
patient and laboratory is included. The total number of tested isolates, the number of resistant isolates, and 
the resistance percentage with a 95% confidence interval are presented in the Finres-report. The resistance 
result from a certain laboratory is included in the Finres-report only if they have tested more than 50 % of 
their isolates against a certain antimicrobial, to avoid biasing caused by broader testing of certain types of 
subpopulations. 
 
2.3.5 Quality assurance 
Quality assurance has an important role in ensuring validity and comparability of susceptibility results. 
According to GLP (Good Laboratory Practice), in every clinical microbiology laboratory each new batch of 
reagents (growing media, antimicrobial disc/ -strip and MIC-card/ -well plate for automated readers) is 
tested with control strains recommended by CLSI (or EUCAST since 2011).  
Comparability of results between different laboratories is best ensured by external quality assessment.  
External quality assessment services are provided by the domestic Labquality Ltd., and the British 
UKNEQAS. The FiRe laboratories also annually participate in the EARS-Net External Quality Assessment 
exercise, where laboratories are asked to determine the antimicrobial susceptibility of six EARS-Net 
pathogens (S. pneumoniae, S. aureus, E. coli, K. pneumoniae, P. aeruginosa and E. faecium). 
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Figure 2.1: The collection of Finres-material 
 
References: 
(1) National Committee for Clinical Laboratory Standards (NCCLS). 2002. Analysis and presentation of cumulative susceptibility 
test data; approved guideline. NCCLS document M39-A. NCCLS, Wayne, Pa. 
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2.4 Bacterial isolates and sample types in the Finres-report 
Annually collected antimicrobial susceptibility data on 15 of the clinically most important bacteria has been 
aggregated into Finres reports since 1997. Data has been collected from bacterial strains isolated from 
clinical samples, and susceptibility results have been produced by routine laboratory methods. An extensive 
collection of resistance data from all Finnish clinical laboratories started in 1997 when the FiRe 
laboratories had adopted a common standard for susceptibility testing. At the beginning, bacterial findings 
were divided into hospital and health care center isolates. This segmentation however, appeared to be too 
vague and therefore in 2005, the FiRe board decided to abandon it. At that time practically all laboratories 
had started sending their data in the WHONET format, which enabled a more precise and reliable 
classification (e.g. based on sample type and patient age). The number of bacterial isolates in the Finres-
database has increased year by year; in 2010 the Finres-database included over 400 000 bacterial isolates 
and over 3 million antimicrobial susceptibility test results. The numbers of isolates of each bacterial species 
are found in Table 2.4. 
For this Finres 1997–2010 –report, resistance data has been collected from the following bacteria-
antimicrobial agent –combinations (the Finres pathogens Klebsiella oxytoca, Enterobacter cloacae and 
Neisseria meningitidis are not included.). 
 
Streptococcus pneumoniae. Until 2004, Finres contains susceptibility data from all clinical S. pneumoniae 
findings. Since 2005, susceptibility data has been collected separately from blood isolates, and pus isolates 
collected from children under and over 5 years. Susceptibility data is collected for the following 
antimicrobials: oxacillin (screening test for penicillin resistance), erythromycin, clindamycin, tetracycline 
and trimethoprim-sulfa. Oxacillin-susceptible strains are interpreted as penicillin-susceptible, but a 
penicillin MIC result is always required if the strain is oxacillin-resistant. 
 
Haemophilus influenzae. Since 1997, susceptibility data from all clinical H. influenzae isolates have been 
gathered for the following antimicrobials: ampicillin, amoxycillin-clavulanate, tetracycline and 
trimethoprim-sulfa. In addition, the β-lactamase production of the strain is noted. β-Lactamase-positive 
strains are always interpreted as ampicillin-resistant. If the strain is ampicillin-resistant but β-lactamase 
negative, the ampicillin susceptibility is based on the MIC result. In these cases, ampicillin resistance is 
interpreted as resistance to amoxycillin-clavulanate as well. 
 
Moraxella catarrhalis. Since 1997, susceptibility data from all clinical M. catarrhalis isolates have been 
gathered for the following antimicrobials: ampicillin, amoxycillin-clavulanate, erythromycin, tetracycline 
and trimethoprim-sulfa. In addition, the β-lactamase production of the tested strain is taken into account. β-
Lactamase positive strains are always interpreted as ampicillin-resistant. 
 
Streptococcus pyogenes. Until 2004, Finres contains susceptibility data for all clinical S. pyogenes findings. 
Since 2005, susceptibility data has been collected separately from throat and pus isolates. Susceptibility 
data is collected for erythromycin and clindamycin. 
 
Escherichia coli. Until 2004, Finres contains susceptibility data for all clinical E. coli findings, divided into 
hospital and health care center isolates. Since 2005, susceptibility data has been collected separately from 
blood and urine isolates, and divided into the patient groups under and over 75 years. 
 
Klebsiella spp. Until 2004, Finres contains susceptibility data from all Klebsiella findings, isolated from 
hospitals. Since 2005, susceptibility data has been collected from Klebsiella pneumoniae, isolated from 
urine and blood samples. 
Susceptibility data on E. coli and Klebsiella spp. is collected for the following antimicrobials: For blood 
isolates ampicillin (E. coli), piperacillin-tazobactam, cefuroxime, cefotaxime/ceftriaxone, ceftazidime, 
imipenem/meropenem, tobramycin, netilmycin, norfloxacin/ofloxacin/ciprofloxacin/ levofloxacin and 
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trimethoprim-sulfa. For urine isolates mecillinam, cephalexin, cefuroxime, norfloxacin/ 
ofloxacin/ciprofloxacin, nitrofurantoin, trimethoprim and trimethoprim-sulfa. If the laboratory identified 
the strain to be an ESBL producer, all 3rd generation cephalosporin S or I results are interpreted as R. This 
rule was changed after the adoption of the EUCAST standard. 
 
Pseudomonas aeruginosa. Until 2004, Finres contains susceptibility data from all P. aeruginosa findings 
isolated from hospitals. Since 2005, susceptibility data has been collected from blood sample isolates. 
Susceptibility test data is presented for the following antimicrobials: piperacillin-tazobactam, ceftazidime, 
imipenem/meropenem, tobramycin and ciprofloxacin. 
 
Acinetobacter spp. Until 2004, Finres contains susceptibility data from all Acinetobacter spp. findings 
isolated from hospitals. Since 2005, susceptibility data has been collected from Acinetobacter sp. and 
Acinetobacter baumannii other than urine sample isolates. Susceptibility test data is presented for the 
following antimicrobials: imipenem/meropenem, tobramycin, netilmycin, ciprofloxacin/levofloxacin and 
trimethoprim-sulfa. 
 
Staphylococcus aureus. Until 2004, Finres contains susceptibility data from all clinical S. aureus findings, 
divided into hospital and health care center isolates. Since 2005, susceptibility data has been collected 
separately from blood and pus isolates. Susceptibility data is presented for the following antimicrobials: 
oxacillin, erythromycin, clincamycin, tetracycline, trimethoprim-sulfa, tobramycin, netilmycin (blood 
isolates), vancomycin, rifampicin and fusidic acid. 
 
Enterococcus spp. Until 2004, Finres contains susceptibility data from all E. faecalis and E. faecium 
findings, isolated from hospitals. Since 2005, susceptibility data has been collected from all clinical 
Enterococcus spp. isolates without grouping to species level. Susceptibility data is presented for the 
following antimicrobials: ampicillin, vancomycin, teicoplanin and nitrofurantoin. 
 
Neisseria gonorrhoeae. Finres contains susceptibility data from all clinical N. gonorrhoeae findings since 
1997. Susceptibility data is presented for ciprofloxacin and cefotaxime/ceftriaxone. 
Table 2.3: The annual variation in the number of bacterial isolates in the Finres-database (1997–2010) 
Pathogen Median Mean value Range 
S. pneumoniae 4 703 4 742 4 217–5 845 
H. influenzae 4 039 4 001 2 491–5 388 
M. catarrhalis 1 936 2 058 1 559–2 731 
S. pyogenes 11 962 13 088 8 007–21 058 
E. coli 106 165 105 587 68 733–128 883 
Klebsiella spp. 10 297 9 863 4 249–15 126 
P. aeruginosa 8 166 9 120 7 091–13 455 
Acinetobacter spp. 1 568 1 758 1 525–2 535 
S. aureus 32 747 32 963 30 478–37 084 
Enterococci 27 479 27 239 14 510–39 670 
N. gonorrhoeae 163 155 100–219 
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3 Antimicrobial resistance in clinically 
important pathogens 
3.1 Antimicrobial resistance in Streptococcus pneumoniae (1988–2010) 
 
 
 
 
 
 
 
 
 
Streptococcus pneumoniae is one of the most common and important pathogens in our country. In Finland 
there are approximately 500 000 cases of otitis media annually (1) of which 26–60 % are caused by 
pneumococci (2). The incidence of community acquired pneumonia in different studies varies from 700 to 
2000 cases / 100 000 habitants / year; pneumococci being the main cause (3). The incidence of invasive 
pneumococcal disease in Finland during the first decade of the 21th centrury has been 14–17 cases/100 000 
habitants / year (4). The highest disease burden is focused on small children and elderly people. Invasive 
pneumococcal infections can be prevented by vaccination.  
The FiRe network has followed the susceptibility of S. pneumoniae towards penicillin, erythromycin, 
clindamycin, tetracycline and trimethoprim-sulfa since 1988. When the surveillance started, resistance was 
practically non-existent. Since then, resistance to all of these antimicrobials has increased dramatically 
(Fig. 3.1), and there are no signs of a brighter future. 
Penicillins 
Penicillins are the most important antimicrobial group in the treatment of pneumococcal infections. FiRe 
has collected data separately for penicillin-resistant pneumococci (PEN R) and penicillin-non-susceptible 
(PEN I+R) pneumococci. In 1996, the proportion of penicillin-non-susceptible isolates was 6 %, and 
remained quite stable until 2000. Thereafter the proportion of PEN I+R pneumococci increased by 
approximately 1.3 % per year. In 2010, penicillin-non-susceptibility was detected in almost 20 % of all 
pneumococcal isolates (Fig. 3.1). 
The proportion of penicillin-resistant S. pneumoniae has slightly increased since 2003, but has remained 
below 3 % until 2010, when this landmark was passed. The proportion of PEN R –strains isolated from 
blood and cerebrospinal fluid has remained under 2 % for the whole study period (Fig. 3.2). 
Macrolides and lincosamides 
Erythromycin resistance among S. pneumoniae isolates has increased substantially: between 1988 and 1990 
less than 1 % of isolates were resistant whereas in 2009 already over 25 % were resistant (Fig. 3.1). 
Erythromycin resistance is even higher among pus isolates collected from small children (Fig. 3.3). 
Macrolide-resistant pneumococci are commonly penicillin non-susceptible and usually telithromycin 
susceptible (5). 
Resistance to clindamycin is more uncommon than erythromycin resistance. Between 2000 and 2007, 
the proportion of clindamycin-resistant S. pneumoniae was 6–11 %, and in 2010 circa 13 %. Roughly one 
third of the erythromycin-resistant isolates are clindamycin-resistant. This correlates well with the most 
common macrolide resistance mechanism in Finland (5), which causes resistance to 14- and 15-membered 
The pneumococcus 
Typical infections: 
? Pneumonia, otitis media, sinusitis, invasive infections (sepsis and meningitis) 
The effect of the antimicrobial resistance situation on treatment options: 
? The penicillin dose should be large and frequent enough  
? Macrolides cannot be recommended for the treatment of pneumococcal infections without 
susceptibility testing 
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macrolides (i.e. erythromycin, roxithromycin, clarithromycin and azithromycin) but not to other 
macrolides, clindamycin and streptogramins. 
Resistance to other antimicrobials 
Resistance to tetracycline is as common as clindamycin resistance in S. pneumoniae isolates. Resistance to 
trimethoprim-sulfa is lower than to erythromycin (Fig. 3.1). Resistance to fluoroquinolones (levofloxacin, 
moxifloxacin) is still quite uncommon. In a S. pneumoniae material collected from the FiRe-laboratories in 
2002, there were less than 2 % fluoroquinolone-resistant isolates (5) but in invasive isolates 
fluoroquinolone resistance has been detected in only sporadic cases (6). 
Multidrug-resistance (non-susceptibility to penicillin, erythromycin and tetracycline) among blood and 
cerebrospinal fluid isolates was unknown at the end of the 1990’s, and thereafter the proportion of 
multidrug-resistance has varied between 1.4 and 5.4 % (4). In pus, the proportion of multidrug-resistant 
isolates is somewhat higher (5). So far multidrug-resistant isolates have remained susceptible to 
fluoroquinolones and ceftriaxone (5, 6). 
Summary 
Antimicrobial resistance in S. pneumoniae has increased during the last decade. Macrolide resistance is so 
common that macrolides cannot be recommended for the treatment of S. pneumoniae infections without 
prior susceptibility testing. The good news is that penicillin resistance is still quite rare, and penicillins can 
be used for the treatment of non-invasive pneumococcal infections, as long as the proper dosage and 
frequency are used.  
Antimicrobial resistance in S. pneumoniae varies among sample types, geographical location, bacterial 
clones and serotypes (5, 6). The hepta-valent pneumococcal conjugate vaccine was added to the national 
vaccination programme in autumn 2010. This vaccine covers up to 80 % of erythromycin resistant and 
penicillin-non-susceptible S. pneumoniae isolates (6). The conjugate vaccine is expected to decrease the 
number of invasive pneumococcal infections markedly. According to preliminary information, the number 
of severe pneumococcal infections among small children has already started to decrease. The future will 
show what effect the vaccine has on antimicrobial resistance in S. pneumoniae.  
 
Figure 3.1: Antimicrobial resistance in S. pneumoniae between 1988 and 2010. PEN R: penicillin-resistant 
pneumococci, PEN I+R: penicillin-non-susceptible pneumococci (7,8). 
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Figure 3.2: Antimicrobial resistance in S. pneumoniae blood isolates from 2005 to 2010. 
 
Figure 3.3: Antimicrobial resistance in S. pneumoniae pus isolates, collected from children under 5 years 
from 2005 to 2010. 
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3.2 Antimicrobial resistance in Haemophilus influenzae (1978–2010) 
 
 
 
 
 
 
 
 
Nowadays Haemophilus influenzae is one of the most common causes of acute otitis media in small 
children, and acute sinusitis, along with S. pneumoniae and Moraxella catarrhalis. Septic infections and 
meningitis in small children, caused by serotype b (Hib) have become more uncommon due to the Hib-
vaccination that was introduced into the national vaccination programme in the mid 1980’s.  
The most important and common antimicrobial resistance mechanism among H. influenzae is the beta-
lactamase mediated ampicillin resistance. This resistance mechanism was described for the first time in the 
beginning of the 1970’s, and in Finland in 1976 (1). Beta-lactamase mediated ampicillin resistance in H. 
influenzae is caused by the same TEM-1, or less frequently TEM-2, which cause ampicillin resistance also 
in Escherichia coli. Ampicillin resistance among H. influenzae spread rapidly and reached its present level 
(20 %, fig. 3.4) in the beginning of the 1980’s (2, 3). It is on the same level elsewhere in the western 
industrialized world (6). Otitis media care guidelines recommending avoidance of eardrum perforation has 
been in use in Finland since the 1990’s. This might have caused biasing of the collected material, since 
only complicated cases were cultured hereafter, and the bacteria might have been under selection pressure 
from previous antimicrobial treatments. Between 1994 and 1995, as preliminary pneumococcal vaccination 
research, 174 H. influenzae strains from unselected otitis samples were investigated in the Pirkanmaa 
hospital district, and this study showed that the prevalence of ampicillin resistance was 10 % among the 
first four infections and 30 % if the infant had had more than four infections (4).  
Mutations in the penicillin-binding proteins (PBP) may also cause ampicillin resistance in H. influenzae 
isolates. These beta-lactamase-negative ampicillin-resistant (BLNAR) strains are also resistant to 
amoxycillin-clavulanate, and 2nd generation cephalosporins, which are not very efficient for the eradication 
of H. influenzae (5). The true prevalence of BLNAR strains is hard to get, since they have low-level 
resistance which is difficult to detect (a BLNAR strain resists only ten times more ampicillin than a 
susceptible strain). In Finland as well as in other industrialized countries the percentage of BLNAR strains 
has remained low at 1–2 % (6). 
In addition to beta-lactam antimicrobials, H. influenzae infections can also be treated with doxycycline 
and trimethoprim-sulfa, whereas macrolides might not be effective (5) and according to EUCAST there is 
only a weak correlation between the MIC value and clinical effect. Tetracycline resistance is uncommon, 
but resistance to trimethoprim-sulfa has reached 15–20 % (Figure 3.5), in line with to other industrialized 
countries (6). Finnish Current Care Guidelines recommends the use of amoxycillin as the first line 
antimicrobial for the treatment of acute otitis media and sinusitis; this recommendation applies well to H. 
influenzae in the current resistance situation. 
 
H. influenzae 
Typical infections: 
? Otitis media, sinusitis, exacerbation of chronic obstructive pulmonary disease (COPD)  
The effect of the antimicrobial resistance situation on treatment options: 
? No effect at the moment 
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Figure 3.4: Beta-lactamase mediated ampicillin resistance in H. influenzae between 1978–2010 (2, 3). 
 
Figure 3.5: Antimicrobial resistance (other than beta-lactamase mediated) in H. influenzae between 1995 
and 2010 (3). 
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3.3 Antimicrobial resistance in Moraxella catarrhalis (1978–2010)  
 
 
 
 
 
 
 
Moraxella catarrhalis is one of the most common causes of infant acute otitis media, acute sinusitis and 
exacerbation of chronic obstructive pulmonary disease (COPD) (1).  
Almost all M. catarrhalis strains are ampicillin-resistant. Ampicillin resistance is caused by the 
production of a beta-lactamase, which to some extent also hydrolyses 2nd generation cephalosporins 
(cefuroxime, cefaclor). M. catarrhalis (previously Branhamella catarrhalis) was identified as a pathogen 
only a few decades ago, and at that time all Finnish strains were susceptible to penicillins. At the end of the 
1970’s, the first beta-lactamase producing M. catarrhalis strains appeared and thereafter beta-lactamase- 
mediated ampicillin resistance has increased rapidly (2, 3), reaching the present 90 % resistance level at the 
beginning of the 1990’s (figure 3.6). All M. catarrhalis strains are still susceptible to amoxycillin-
clavulanate. In addition, M. catarrhalis is almost totally susceptible to second line antimicrobials, 
macrolides, tetracyclines and trimethoprim-sulfa (Figure 3.7).  
 
 
Figure 3.6: Beta-lactamase mediated ampicillin resistance in M. catarrhalis between 1978–2010 (2,3). 
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M. catarrhalis 
Typical infections: 
? Otitis media, sinusitis, exacerbation of chronic obstructive pulmonary disease (COPD) 
The effect of the antimicrobial resistance situation on treatment options: 
? No effect at the moment 
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Figure 3.7: Erythromycin, tetracycline and sulfa/trimethroprim resistance in M. catarrhalis between 1995 
and 2010 (3).  
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3.4 Antimicrobial resistance in Group A streptococci (1991–2010) 
 
 
 
 
 
 
 
Streptococcus pyogenes, also known as the group A streptococcus, causes throat and skin infections and 
sometimes also septic infections. Penicillin has been the first-line drug in the treatment of group A 
streptococcal infections for the last 70 years. During this time, penicillin or cephalosporin resistant strains 
have never been found, and S. pyogenes is thus consistently susceptible to these agents.  
However, resistance to other antimicrobials occurs. Besides penicillin and 1st generation cephalosporins, 
macrolide antimicrobials and clindamycin can also be used for the treatment of group A streptococcal 
infections. Erythromycin is used for macrolide (azithromycin, clarithromycin and roxithromycin) 
susceptibility testing. 
In the beginning of the 1990’s, macrolide resistance in group A streptococci was at its highest level, in 
some regions over 40 %. Because of treatment failures – some even leading to seriuos complications 
demanding hospitalization – during macrolide treatment of infections caused by resistant strains, a 
recommendation was given to avoid the use of macrolides for the treatment of throat and skin infections 
(1). For outpatients with penicillin allergy, 1st generation cephalosporins were recommended as a first-line 
drug, if the patient had no previous anaphylactic reactions to penicillin derivates. Following this 
recommendation, macrolide resistance fell to 5–10 % within a few years. In the 2000’s, macrolide 
resistance decreased further, and has stabilized at 2–4 % between 2002 and 2010 (Figure 3.8). 
Clindamycin resistance has remained at a low level, 0–2 %, from 2000–2010, but a slight increase can 
be detected. Clindamycin can be important in the treatment of severe group A streptococcal infections and 
for patients with penicillin allergy. Although clindamycin and macrolides have related mechanisms of 
action, clindamycin resistance is far more uncommon than macrolide resistance. This is due to the different 
resistance mechanisms towards these employed by the group A streptococcus. 
 
Figure 3.8: Antimicrobial resistance in Group A streptococci between 1991 and 2010. 
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3.5 Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter spp. 
3.5.1 Background 
 
The cell envelope of gram-negative bacteria consists of a cell wall built of an outer glycosylated lipid 
bilayer and a thin peptidoglycan layer, the periplasmic space, and an inner phospholipid membrane.  
The outer lipid layer forms an efficient barrier to antimicrobial penetration. The development of new 
antimicrobials against infections caused by gram negative bacteria is therefore challenging. Since there are 
no new antimicrobials in sight, surveillance of the resistance towards antimicrobials now in use is 
particularly important.  
Finres data has been collected since 1991. In the earliest material, ampicillin resistance was a notable 
exception amongst the otherwise very susceptible bacteria. The cause of this, the β-lactamase TEM-1, was 
common already then. Also trimethoprim resistance levels were fairly high. The situation has been 
worsening in the new millennium. The most important change has been the increase of strains producing 
extended spectrum β-lactamases (ESBL). They were found already in the 1990’s, but mainly among K. 
pneumoniae strains, and in low numbers. The Finres data clearly shows the change that has occurred 
among E. coli strains. ESBL strains have become more prevalent, and the increase is steady among clinical 
strains. 
Carbapenem-resistant Enterobacteriaceae strains have increased globally at an alarming rate. In Finland 
we have so far seen only sporadic cases involving carbapenemase-producing E. coli, Klebsiella spp. and 
Enterobacter cloacae strains. Among the non-fermenting rods P. aeruginosa and Acinetobacter spp., the 
situation is different; finding a carbapenem-resistant strain is no surprise, and small recurrent epidemics 
have already been seen. But strains producing carbapenemase enzymes are still rare. Effective 
antimicrobial treatment can still be found for the majority of infections caused by these strains, but strains 
resistant to all antimicrobials have been reported, mainly from the capital hospital district, HUS, and a few 
cases also from other parts of Finland. The Finres data clearly shows that the majority of Finnish strains are 
still susceptible to most antimicrobials. 
 
3.5.2 Antimicrobial resistance among Escherichia coli 1997-2010 
 
 
 
 
 
 
 
 
 
Escherichia coli is the clinically most significant species among the Enterobacteriaceae. It is the most 
common cause of lower urinary tract infection. It also causes serious infections, of which the most 
important is pyelonephritis and its complication urosepsis. In addition to anaerobes, E. coli is also 
important in intra-abdominal infections, such as peritonitis following an appendix perforation. Some strains 
cause food-borne intestinal infections. 
The increase of ESBL-producing strains is a significant factor in the development of resistance in E. 
coli, since these strains are usually resistant, in addition to β-lactams, also to several unrelated antimicrobial 
E. coli 
Typical infections: 
? Urinary tract infection, pyelonephritis, urosepsis, food borne intestinal infections 
The effect of the antimicrobial resistance situation on treatment options: 
? First line antimicrobials for urinary tract infections, especially mecillinam and 
nitrofurantoin, have remained effective. Resistance levels to fluoroquinolones have gone 
up. 
? ESBL-producing multiresistant strains are increasing at a worrying pace; this decreases 
the available number of effective antimicrobials. 
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groups (fluoroquinolones, trimethoprim, aminoglycosides, tetracyclines). This multiresistance has 
important clinical consequences. Multiresistant strains increase mortality especially among seriously ill 
patients, prolong hospitalization, and increase costs (1). ESBLs are discussed in a separate section (3.5.4). 
Resistance of E. coli to carbapenems is so far very rare (section 3.5.5 and Figure 3.13). 
Susceptibility data on E. coli in the Finres database was grouped first as either healthcare center or 
hospital isolates (the years 1997-2004, Figures 3.9 and 3.10), then as urinary tract or blood isolates (the 
years 2005-2010, Figures 3.11, 3.12, 3.13). The urinary tract isolates were further divided into isolates from 
patients younger than 75 years, and 75 years or over (Figures 3.11 and 3.12). As can be seen in these 
figures, ampicillin resistance is common (20-30%). In 2010 it was 34 % in blood isolates. This is explained 
by a high prevalence of ampicillin-hydrolyzing enzymes, especially TEM-1. Cephalothin is representing 
the first generation cephalosporins, and resistance is 8-10 % in this material. The spread of ESBL genes 
also affects ampicillin and cephalothin resistance levels. Mecillinam, usually used as the oral 
pivmecillinam, also belongs to the β-lactams, but according to current knowledge it is not affected by the 
TEM-1 enzyme. The majority (>96 %) of the E. coli strains in the Finres material is susceptible to 
mecillinam. Because of the increase of ESBL strains there has been a rising interest towards mecillinam in 
the treatment of lower urinary tract infections, and new research into the effectiveness of mecillinam will 
probably be reported in the near future. Nitrofurantoin has also remained effective against E. coli, and only 
a few percentages are resistant. It is also very effective for urinary tract infections, if the patient tolerates it. 
Nitrofurantoin cannot be used e.g. if kidney function is lowered. Fluoroquinolone resistance (to 
norfloxacin, ciprofloxacin or levofloxacin) is below 10 % in the Finres material. There is however a very 
worrying increasing trend, which might be explained by the increase of ESBL strains, which commonly are 
co-resistant also to fluoroquinolones. For trimethoprim, there was a decreasing trend before 2004. After 
that, the prevalence levelled out, and even increased among <75-year old patient isolates. The overall 
resistance level is now fairly high at 17–19 %. 
 
Figure 3.9: Antimicrobial resistance in E. coli strains, isolated from health care centers between 1997 and 
2004. 
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Figure 3.10: Antimicrobial resistance in E. coli strains, isolated from hospitals between 1997 and 2004. 
 
Figure 3.11: Antimicrobial resistance in E. coli strains, isolated from urine samples taken from patients 
under 75 years old (2005–2010). 
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Figure 3.12: Antimicrobial resistance in E. coli strains isolated from urine samples taken from patients 
over 75 years old (2005–2010). 
 
Figure 3.13: Resistance against the most important antimicrobials used in hospitals, in E. coli strains 
isolated from blood cultures. 
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3.5.3 Antimicrobial resistance among Klebsiella spp. 1997-2010 
 
 
 
 
 
 
 
 
Klebsiellas belong to the normal human intestinal and oral microbiota. A third of humans carry Klebsiella 
species in their gut, and hospitalization and antimicrobial use increase prevalence (1). Klebsiellas cause 
urinary tract infections, hospital aqcuired pneumonias and septic infections. The infecting strain is usually 
derived from the gut flora of the patient, but klebsiellas can persist in different environments, such as on the 
hands of personnel, wash basins and ventilators. Possible routes of infection are therefore many (2). 
Klebsiellas can be found also in food, soil and water (1), but pathogenicity, and probably also antimicrobial 
resistance rates, might be lower in such strains (3).  
K. pneumoniae is the most common species in clinical samples. The former Klebsiella species 
Raoultella terrigena and Raoultella planticola are phenotypically so similar to K. pneumoniae that 
biochemical differentiation of these species may be difficult. The raoultellas were delineated as a new 
genus in 2001 (4), therefore the older Finres data comprise also these species. Raoultella spp. appears to be 
more common in Europe, compared to the US and Brazil (3). K. oxytoca is also commonly found in clinical 
samples. Phenotypical differentiation is straight forward and important because it differs slightly in its 
innate resistance. 
Antimicrobial resistance based on Finres-data in 1997-2004 and 2005-2010 
In 1997-2004, susceptibility data was collected on all Klebsiella spp. The data was divided into hospital 
and open care (healthcare center) isolates (Figure 3.14). From 2005 onwards, data on K. pneumoniae only 
has been collected, and this is divided into urinary tract (including hospital and open care) and blood 
isolates (Figures 3.15 and 3.16). Thus the two time periods are not directly comparable. 
Resistance has remained low, below 5 %, to cephalosporins, fluoroquinolones, aminoglycosides and 
carbapenems during both time periods, and any clear changes cannot be seen. The data for nitrofurantoin 
and mecillinam is interesting: during the first time period, 1997-2004, there was a reduction in resistance. 
The number of tested strains is large; thus the finding is probably not due to statistical variation. E.g. the 
number of strains tested against mecillinam was 5188 in 1997, and varies between 3897 and 6802 during 
2000-2004. The decline did not continue after 2005. 
There was a transient increase in trimethoprim and trimethoprim-sulfa resistance during 2004-2006. The 
phenomenon was seen both among blood and urine isolates, and resistance levels were evenly distributed 
throughout the country. We have no explanation for this; one possibility might be the spread of a resistant 
clone. The Finres data does not suffice to prove this. 
Klebsiella 
Typical infections: 
? Urinary tract infections, hospital acquired pneumonia, septic infections 
The effect of the antimicrobial resistance situation on treatment options: 
? No effect at present 
? Sporadic almost panresistant strains may occur 
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Figure 3.14: Antimicrobial resistance in Klebsiella spp., isolated from hospital patients 1997 – 2004. 
 
 
Figure 3.15: Antimicrobial resistance in K. pneumoniae, isolated from urine samples 2005 – 2010. 
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Figure 3.16:  Antimicrobial resistance in K. pneumoniae, isolated from blood samples 2005 - 2010 
References: 
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(4) Phylogenetic analyses of Klebsiella species delineate Klebsiella and Raoultella gen. nov., with description of Raoultella 
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3.5.4 Bacteria producing extended-spectrum β-lactamases (ESBL) 
β-Lactamases are enzymes produced by bacteria, which can break down antimicrobials having a β-lactam 
ring, e.g. penicillins, and thus render the bacterium resistant to this antimicrobial. Extended-spectrum β-
lactamases (ESBL) can break down penicillins, extended-spectrum cephalosporins (e.g. ceftriaxone) and 
monobactams (aztreonam), but not carbapenems (imipenem, meropenem, ertapenem). ESBL genes are 
found in the family Enterobacteriaceae. Clinically most significant are ESBL producing E. coli and K. 
pneumoniae strains. ESBL producing strains are often also resistant to fluoroquinolones, aminoglycosides, 
trimethoprim and tetracycline (1), which complicates antimicrobial therapy. 
The change in the epidemiological situation in Finland 
There has been a global change in the prevalence of ESBL genes, and the species in which they occur. The 
first ESBL genes were found already in the beginning of the 1980’s (2). They were usually found in K. 
pneumoniae, and the genes were ESBL variants of TEM and SHV genes (3). A fast increase in ESBL 
producing strains was noticed in the UK at the beginning of the 2000’s.  This was caused by E. coli strains 
carrying CTX-M genes. 
In Finland, the development mirrors the situation globally. In the 1990’s, ESBL strains were rare, and 
the genes similar to those then reported. In the FiRe report published in 1997, 0.6% of E. coli strains, and 
2.3% of K. pneumoniae strains were resistant to 3rd generation cephalosporins (4). These strains had TEM 
and SHV genes. During the 2000’s, the situation has changed, and the ESBL problem has worsened. In a 
representative material covering all of Finland from the years 2002-2004, CTX-M-group genes were 
already found in 90 % of all ESBL producing E. coli strains. Also in K. pneumoniae, CTX-M genes were 
the most common (5). ESBL production has been notified separately in the Finres data since 2007. The 
prevalence of ESBL strains is increasing steadily (Figures 3.17 and 3.18). In 2011, 4.6 % of E. coli blood 
isolates, and over 2 % of urine isolates were ESBL producers. The corresponding numbers for K. 
pneumoniae were 1.7 % and 1.0 %. The clear rising trend among E. coli isolates is not mirrored among K. 
pneumoniae. It is currently not known how widespread ESBL carriage in fecal flora in the community is in 
Finland, but e.g. travel can increase the risk of colonisation. E. coli is an important cause of uncomplicated 
open care urinary tract infections, and it is conceivable that the increase in ESBL infections is caused by 
more widespread colonisation of the Finnish population. K. pneumoniae strains are still more seen in 
hospital infections, and changes in prevalence are affected by transient hospital epidemics. The number of 
blood isolates is small, and thus even small changes can cause large variation in resistance percentages: e.g. 
the sudden rise in 2010 consists of 15 isolates (Figure 3.18). 
The resistance among E. coli and K. pneumoniae against the most important hospital antibiotics is still 
relatively rare (Section 3.5.2 Figure 3.13 and Section 3.5.3 Figure 3.14). ESBL producing strains are 
multiresistant, and their increase affects the usefulness also of other antibiotics than β-lactams. 
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Figure 3.17: ESBL producing Escherichia coli isolates from 2007 to 2010. 
 
Figure 3.18: ESBL producing Klebsiella pneumoniae isolates from 2007 and 2010. 
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3.5.5 Carbapenem resistance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Carbapenems (imipenem, meropenem, ertapenem) are considered last-resort antibiotics, since they are the 
only antimicrobial group that has remained broadly effective against gram-negative bacteria. They belong 
to the β-lactams, and are thus well tolerated and effective. However, resistance among gram-negative 
bacilli is increasing at an alarming rate globally. This concerns especially Enterobacteriaceae species such 
as E. coli and K. pneumoniae, but also the non-fermenting rods P. aeruginosa and Acinetobacter baumannii 
(1, 2). Gram-negative bacteria that are resistant to carbapenems are also very often resistant to several other 
antimicrobial classes, or even to all available antibiotics, which causes significant treatment problems (3). 
Resistance towards carbapenems can develop through several mechanisms, and enzymes which break down 
carbapenemases are the most important resistance mechanisms, that have to be monitored. This should be 
remembered especially for non-fermenting species, since other mechanisms are common among them. 
Carbapenemase-producing strains are found especially in the hospital environment, but according to recent 
findings they can also appear in community-acquired infections, when the patient has had contact to a 
country (e.g. India) where these bacteria are endemic. 
Carbapenems (imipenem, meropenem, ertapenem) are considered last-resort antibiotics, since they are 
the only antimicrobial group that has remained broadly effective against gram-negative bacteria. They 
belong to the β-lactams, and are thus well tolerated and effective. However, resistance among gram-
negative bacilli is increasing at an alarming rate globally. This concerns especially Enterobacteriaceae 
species such as E. coli and K. pneumoniae, but also the non-fermenting rods P. aeruginosa and 
Acinetobacter baumannii (1, 2). Gram-negative bacteria that are resistant to carbapenems are also very 
often resistant to several other antimicrobial classes, or even to all available antibiotics, which causes 
significant treatment problems (3). Resistance towards carbapenems can develop through several 
mechanisms, and enzymes which break down carbapenemases are the most important resistance 
mechanisms, that have to be monitored. This should be remembered especially for non-fermenting species, 
since other mechanisms are common among them. Carbapenemase-producing strains are found especially 
in the hospital environment, but according to recent findings they can also appear in community-acquired 
infections, when the patient has had contact to a country (e.g. India) where these bacteria are endemic. 
In the surveillance of carbapenem resistance, Enterobacteriaceae and non-fermenters should be 
separated, both because of their differing pathogenicity and the often different mechanisms. In Sections 
3.5.2 and 3.5.3, the resistance development of E. coli and K. pneumoniae from 2005 to 2010 are presented. 
As can be seen in Figures 3.13 and 3.16, there are practically no carbapenem resistant strains. At present, 
on average one carbapenemase-producing strain belonging to the family Enterobacteriaceae is isolated per 
month in Finland (4). The majority of patients have been abroad. The most common carbapenemase genes 
found are OXA-48/181, KPC, VIM and NDM. 
In the case of non-fermenting gram-negative species, the carbapenems are an important antibiotic 
group, since these species have innate resistance to several other classes of antibiotics. The resistance 
P. aeruginosa 
Typical infections: 
? Opportunistic hospital infections, skin and soft tissue infections 
The effect of the antimicrobial resistance situation on treatment options: 
? No major effects at present 
? Nearly or completely panresistant strains may be found in the hospital environment 
 
Acinetobacter 
Typical infections: 
? Pneumonia, skin and wound infections, urinary tract infections and opportunistic 
infections 
The effect of the antimicrobial resistance situation on treatment options: 
? No major effects at present 
? Nearly or completely panresistant strains may be found in the hospital environment 
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development towards the most important antimicrobials in P. aeruginosa and Acinetobacter spp. (A. 
baumannii being the most important) is presented in Figures 3.19 and 3.20. There are more carbapenem 
resistant strains than among Enterobacteriaceae. The levels vary, and there is no clear trend at least for 
Acinetobacter. For P. aeruginosa, there might be a slight increase; this must be closely monitored. Small 
local epidemics probably have an effect. Carbapenemase producing strains are occasionally found, but the 
majority of the resistance is caused by other mechanisms (unpublished data at THL and HUSLAB). There 
has so far been no outbreaks caused by carbapenemase-producing strains, but among immunocompromised 
patients, endemic clonal spread of both Acinetobacter and P. aeruginosa has been obesrved for a long time 
(HUSLAB unpublished data). When carbapenemases are found in P. aeruginosa, they are usually VIM or 
IMP metalloenzymes. In A. baumannii, OXA-carbapenemases have been found (unpublished data at THL 
and HUSLAB). 
As appear from the Figures 3.19 and 3.20, and the Figures in Sections 3.5.2 and 3.5.3, most 
antimicrobials in use are still relatively effective against non-fermenting rods and Enterobacteriaceae. So 
far we have seen strains resistant to nearly all antimicrobials only as single isolations or small clusters. In 
these cases, polymyxins (e.g. colistin) might still be useful. Resistance data on colistin is not yet collected 
into the Finres database. 
 
 
Figure 3.19: Antimicrobial resistance in Pseudomonas aeruginosa, 2005 – 2010.    
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Figure 3.20: Antimicrobial resistance in Acinetobacter spp. from 2005 to 2010 
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3.6 Antimicrobial resistance in Staphylococcus aureus (1991–2010) 
 
 
 
 
 
 
 
 
At least half of all human beings carry Staphylococcus aureus in their nose flora either permanently of 
temporarily. The throat and moist skin areas can also be colonized.  The source of S. aureus infections is 
commonly derived from the patient’s own microbiota, but staphylococci can also be transferred between 
individuals via touching or indirectly via the environment. 
S. aureus is the most important causer of purulent skin infections. Some S. aureus nasal carriers have 
recurrent skin abscesses. Local infection can spread into subcutaneous tissue as cellulitis, and proceed to 
bacteremia. Bacteremia can be followed by severe septic shock or/and metastatic abscesses in internal 
organs. Nowadays S. aureus is one of the most common causes of endocarditis, especially among drug 
users. S. aureus can cause also septic arthritis and osteomyelitis. 
In the beginning of the antimicrobial era, S. aureus was susceptible even to penicillin, but the ability to 
degrade it spread rapidly among S. aureus strains. Penicillinase-resistant staphylococcal penicillins (among 
others methicillin, cloxacillin and oxacillin) were developed to solve this problem. The first methicillin-
resistant S. aureus strains (MRSA) were detected already in the beginning of the 1960’s, only a few years 
after methicillin had appeared on the market. Resistance to methicillin is caused by a protein involved in 
the cell wall synthesis, to which methicillin (and other betalactams) cannot bind and therefore cannot 
inhibit its function.  Methicillin resistance is mediated by the mecA gene (and its recently found variants), 
and it is assumed that it can be transferred between strains. MRSA strains started to spread in hospitals all 
over the world in the 1980’s. In Finland, the first MRSA hospital epidemic was detected in 1991, and by 
the mid 1990’s around 100 MRSA cases were detected annually (1). From 1997 to 2004 the number of 
MRSA findings increased fairly rapidly: in hospitals the number of oxacillin-resistant S. aureus increased 
2.6 times, from less than 2 % to nearly 5 % (Figure 3.21). Similar increase could be seen in healthcare 
center samples: the number of oxacillin-resistant strains increased from less than 1 % to 4 % (Figure 3.22). 
This increase was partly caused by the spread of two international clones in Finland, but also by the 
emergence of outpatient MRSA strains (2). Whereas MRSA strains that have circulated in hospitals 
globally for many years are commonly resistant to several antimicrobial groups, strains isolated from 
outpatients are usually only β-lactam resistant. The development of more sensitive laboratory detection 
methods probably also explains the increased proportion of these strains.  
Luckily, the steep rise of MRSA did not continue between 2005 – 2010.The percentage of MRSA in 
both blood and pus isolates stabilized at 2–3 % (Figures 3.23 and 3.24). There is a significant geographical 
variation: in the Pirkanmaa region (Tampere), MRSA prevalence was 8.1 % in 2010, while in the rest of the 
country is was 0-2.7 % (3). In most hospitals invasive MRSA infections are still uncommon; the Pirkanmaa 
region accounted for nearly 40 % of these. We thus have slightly more invasive MRSA infections in 
Finland as compared to Sweden and Norway, where the proportion of MRSA is less than 1 % of all 
invasive S. aureus infections, but the number is still clearly lower than in Central and Southern Europe (4). 
Strains resistant to vancomycin, the traditional first-line antibiotic against serious MRSA infections, 
have not been found in Finland. Also rifampicin, used in combination with other antimicrobials, can be 
used for the treatment of deep infections caused both by MRSA and “regular” S. aureus strains. In addition, 
S. aureus strains are almost always susceptible to aminoglycosides. 
 
S. aureus 
Typical infections: 
? Skin infections, cellulitis, sepsis, endocarditis 
The effect of the antimicrobial resistance situation on treatment options: 
? No effect at the moment at country level. The MRSA situation should be taken into 
consideration in certain geographical areas 
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The susceptibility to antimicrobials that can be used to treat mild S. aureus infections is also good: only 
about 5 % of all S. aureus strains are macrolide-resistant and 3–4 % clindamycin-resistant. Resistance to 
tetracyclines (1–2 %) and trimethoprim-sulfa (<1 %) is even more uncommon. The topical antibiotic 
fusidic acid is effective against over 95 % of S. aureus strains. 
 
Figure 3.21: Antimicrobial resistance in S. aureus strains, isolated from hospitals 1997 – 2004. 
 
Figure 3.22: Antimicrobial resistance in S. aureus strains, isolated from health care centers 1997 – 2004. 
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Figure 3.23: Antimicrobial resistance in S. aureus blood isolates, 2005 – 2010. 
 
Figure 3.24: Antimicrobial resistance in S. aureus pus isolates, 2005 – 2010. 
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3.7 Antimicrobial resistance in Enterococcus spp. (1991–2010) 
 
 
 
 
 
 
 
 
Enterococcus spp. are an important part of intestinal microbiota of humans and many animals. Enterococci 
are able to adapt to many different growth conditions, and they are intrinsically resistant to many 
antimicrobials. Enterococci have traditionally been regarded as low-grade pathogens and thus infections are 
more common in immune-compromised patients, following procedures where the natural barriers of the 
body have been broken, or after antimicrobial treatments which have decreased the numbers of protective 
bacteria. Urinary tract infections caused by Enterococcus spp. are commonly linked to catheterization or 
other invasive procedures. Enterococcus spp. can also cause hospital-aqcuired bacteremia and a substantial 
part of of bacterial endocardites. Enterococci also appear in the mixed flora of abscesses in the abdominal 
and pelvic area, and in chronic wounds. Up to 80 % of enterococcal infections are caused by E. faecalis, 
which is the clinically most important enterococcus, and of the remaining part, most are caused by E. 
faecium. Since the 1990’s, the role of E. faecium especially in hospital infections has increased. Molecular 
techniques have shown that this is due to the hospital-adapted E. faecium clone CC17, which has 
exceptionally well-developed virulence and resistance determinants (1). 
The penicillin-binding proteins (PBP) in the enterococcal cell wall naturally bind β-lactams very 
weakly. Of the β-lactam antimicrobials, only ampicillin, piperacillin and imipenem are effective against 
Enterococcus spp. E. faecalis is nearly always susceptible to all these, whereas over 80 % of clinical E. 
faecium strains are ampicillin-resistant. Since enterococci from urine samples are not identified to species 
level in every laboratory, it cannot be deduced whether the increase in ampicillin resistance in the 2000’s is 
due to an increased proportion of E. faecium strains, or an increasing level of ampicillin resistance within 
this species (Figure 3.25).   
Due to the widespread β-lactam resistance, vancomycin is the most important antimicrobial agent for 
the treatment of severe E. faecium infections. During the 1990’s the number of vancomycin-resistant E. 
faecium strains increased steeply especially in hospitals in the United States, where VRE is one of the most 
important causes of hospital infections. In Finland, the first VRE cases were detected in 1992 (2). 
According to the National Infectious Diseases Register, the highest number of VRE cases (over 300 cases) 
was detected in 1997 (figure 3.26). The large VRE epidemics in the 1990’s were located in the capital 
healthcare district, and around 2000 in the Vaasa region; in the 2000’s VRE outbreaks have also been 
detected in Northern Ostrobotnia and in  the South-West. The National Infectious Diseases Register also 
includes screening results from carriers, and thus the real number of VRE infections is difficult to obtain 
from that register. In the Finres material, screening samples are not included, and only one bacterial 
finding/sample type/patient/year is included. Here the highest percentage of VRE in the top year 1997 was 
15 %, among E. faecium strains (n= 1974, species identified). Subsequently the percentage of VRE-strains 
has been over 1 % only in 2000, when 1.6 % of E. faecium strains (n=2700) were vancomycin-resistant 
(Figure 3.26). When all Enterococcus spp. isolates are pooled together, this percentage appears as a very 
tiny bar (Figure 3.25). As elsewhere, the majority of VRE cases are E. faecium but vancomycin-resistant E. 
faecalis also exists. 
Nitrofurantoin resistance among Enterococcus spp. has increased markedly since 2005 (Figure 3.25). 
This phenomenon has been seen mainly in E. faecium, but the reason is unknown. On the other hand, 
nitrofurantoin susceptibility testing in E. faecium has been found to be very unreliable, and therefore no 
definitive conclusions can be made about the resistance levels. Since E. faecium is also commonly resistant 
to fluoroquinolones, there are sometimes no oral antimicrobials available to treat urinary tract infections 
caused by this bacterium.  
Enterococci 
Typical infections: 
? Urinary tract infections (especially catheter-related), cellulitis, intra-abdominal and pelvic 
infections, sepsis, endocarditis 
 The effect of the antimicrobial resistance situation on treatment options: 
? No effect at the moment 
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Figure 3.25: Antimicrobial resistance in Enterococcus spp. between 1997 and 2010. 
 
Figure 3.26: VRE cases in Finland (including both clinical and carrier isolates): The percentage of vancomycin-
resistant E. faecium represented by bars (left y-axis) and the number of VRE cases reported to the 
National Infectious Diseases Register is represented by a line (right y-axis). 
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3.8 Antimicrobial resistance in Neisseria gonorrhoeae (2000–2010) 
 
 
 
 
 
 
 
 
 
Neisseria gonorrhoeae is still among the most common sexually transmitted diseases in the world. 
Although endemic gonorrhea was practically eradicated in Finland in the 1990’s, isolated cases have been 
reported evenly throughout the 2000’s, around 240 cases per year (1). The majority of cases are “souvenirs” 
from abroad, with some minor secondary spread. Therefore local antimicrobial stewardship programmes 
would have no effect on the development of resistance.  
After the increase in penicillin resistance among N. gonorrhoeae, fluoroquinolones appeared on the 
market at the end of the 1980s, and became the drug of choice for gonorrhoea all over the world. Thus a 
Finnish treatment recommendation published in 1986 (2), which still recommended the use of penicillins, 
had to be replaced already in 1989 by a recommendation where ciprofloxacin was the first-line treatment 
(3). The first ciprofloxacin-resistant N. gonorrhoeae strains in Finland were described in 1995 (4) and ten 
year later the proportion already exceeded 50% (Figure 3.27). After 20 years of use, ciprofloxacin has come 
to the end of its road in the treatment of gonorrhea in Finland. 
Penicillin resistance in N. gonorrhoea is most commonly caused by mutations in the genes encoding 
penicillin-binding proteins which gradually increase the level of resistance. For a long time this was 
countered by increasing dosages. At the beginning of the penicillin era at the end of the 1940’s, gonorrhea 
could be treated with a dose of 60 000 units, whereas at the end of the 1980’s the dosage needed was 40 
times higher (2). Ceftriaxone has so far maintained its clinical efficacy against N. gonorrhoeae. But 
resistance is gradually increasing (5), and in 2011 the first fully ceftriaxone-resistant strain of N. 
gonorrhoeae was described in Japan (6). Such strains have also been reported in Europe lately.  
So far all tested patient isolates have been ceftriaxone susceptible in Finland, but strains with reduced 
susceptibility have started to appear (Figure 3.28). By increasing the dosage (as with the penicillins!), we 
can manage for a while. 
 
 
 
 
N. gonorrhoeae 
Typical infections: 
? Gonorrhoea: purulent (sometimes symptom-free) urethritis, epididymitis, oviduct infection, 
throat gonorrhea, eye gonorrhea, rectal infection 
The effect of the antimicrobial resistance situation on treatment options: 
? Gonorrhea can no longer be treated with fluoroquinolones 
? 3rd generation cephalosporins need to be used with higher doses 
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Figure 3.27: Ciprofloxacin and ceftriaxone resistance in Neisseria gonorrhoeae from 2000 to 2010. 
 
Figure 3.28: Ceftriaxone MIC distribution of Neisseria gonorrhoeae in 2004 and 2010. 
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4 Resistance surveillance based on 
research projects and other materials 
4.1 Antimicrobial resistance in Salmonella enterica isolates from 1995 to 2009 
 
 
 
 
 
 
 
 
 
 
 
 
 
The development of antimicrobial resistance in Salmonella enterica isolates has been monitored at the 
Antimicrobial Resistance Unit at the National Institute for Health and Welfare (formerly the National 
Public Health Institute) since 1996. During these years, three important phenomena have been detected: an 
increase in strains with reduced fluoroquinolone susceptibility, and also more frequent isolation of both 
qnr- and ESBL-producing S. enterica isolates. All of these originate from Southeast Asia. 
 
Reduced fluoroquinolone susceptibility 
 In 1995 to 2003, reduced fluoroquinolone susceptibility (CIP ≥0.125 mg/L) among foreign S. enterica 
isolates increased from 4 % to 47 %, whereas the increase among domestic isolates was from 0 % to 15 %. 
The increase was most marked among isolates collected from travellers returning from Southeast Asia and 
especially from Thailand, from 6 % to 66 %. From the 1990’s to the beginning of the 2000’s, all S. enterica 
isolates with reduced fluoroquinolone susceptibility were highly resistant to nalidixic acid (NAL ≥64 mg/L) 
and the resistance was caused by mutations in the gyrA gene (1,2). 
 
The Qnr-phenotype 
Since 2003, reduced ciprofloxacin susceptibility has become rarer in all study populations, and in 2009 
only 10 % of domestic, 30 % of foreign and 35 % of isolates with Southeast Asian origin had reduced 
fluoroquinolone susceptibility (Figure 4.1&4.2). At the same time a new resistance phenotype arrived: after 
2003, we have found S. enterica isolates with reduced ciprofloxacin susceptibility that are sensitive or only 
low-level resistant to nalidixic acid (NAL ≤32 mg/L) (3). This new resistance phenotype is plasmid 
mediated, and the qnr genes are easily transferred from one isolate to another. Isolates with gyrase 
mutations were easily detected thanks to their nalidixic acid resistance. Isolates with the qnr phenotype are 
missed if only nalidixic acid is tested; also the ciprofloxacin susceptibility must be determined. Between 
2003 and 2008, the percentage of qnr isolates was around 10%, but decreased to 5% in 2009 (Figure 4.2). 
Practically all qnr positive S. enterica isolates originate from Southeast Asia, mainly Thailand and 
Malaysia (4). 
 
ESBL-producing S. enterica 
In the 1990’s, S. enterica isolates with reduced cefotaxime susceptibility were found rarely. In the 2000’s, 
and especially 2005 onwards, the proportion of cefotaxime nonsusceptible isolates has increased 
substantially, already being over 1% in 2009. Over 50% of these have the ESBL phenotype; the other half 
Salmonella 
Typical infections: 
? Enterites, serious septic general infections 
The effect of the antimicrobial resistance situation on treatment options: 
? Mildly symptomatic patients with no underlying diseases should not be treated with 
antibiotics. 
? Travellers, especially from the Southeast Asia, with severe symptoms should be treated 
according to susceptibility results, and if starting empiric treatment, keep in mind the 
large proportion of fluoroquinolone nonsusceptible strains, and the possibility of strains 
resistant to 3rd generation cephalosporins (ESBL/AmpC). 
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are AmpC producers. Again, the reduced susceptibility is mainly concentrated to S. enterica isolates 
originating from Southeast Asia. In addition, the CTX-M ESBL genes are commonly linked to qnr. 
 
Azithromycin resistance  
Due to increased resistance to fluoroquinolones and cephalosporins, other antimicrobials, like azithromycin, 
have been tested for the treatment of Salmonella infections. Although Salmonella is intrinsically resistant to 
erythromycin, the macrolide derivative azithromycin has shown good in vitro activity against S. enterica 
isolates. Between 2003 and 2008, less than 2 % of the tested S. enterica isolates were resistant to 
azithromycin (AZM ≥32 mg/L), whereas among reduced fluoroquinolone susceptible isolates azithromycin 
resistance was >5 % (5). 
 
MDR 
From 2000 to 2009, the ASSuT resistance profile (resistance to AMP, STR, SUL and TCY) was detected in 
8.1 % of domestic and 6.0 % of foreign S. enterica isolates, and the ACSSuT (CHL in addition to ASSuT) 
resistance profile was detected in 5.0 % of domestic and 2.6 % of foreign S. enterica isolates. Among 
foreign S. enterica isolates, 71 and 56 % of the isolates with ASSuT and ACSSuT resistance profile, 
respectively, originated from Southeast Asia. 
 
 
 
Figure 4.1: Fluoroquinolone resistance in domestic S. enterica isolates 1995–2009. 
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Figure 4.2: Fluoroquinolone resistance in foreign S. enterica isolates 1995–2009. 
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4.2 Antimicrobial resistance Mycobacterium tuberculosis, 1991‒2010 
 
 
 
 
 
 
 
The level of drug resistance for Mycobacterium tuberculosis in Finland has remained low, despite the 
situation in the neighboring countries Russia and Estonia, where isolates resistant to the two most important 
TB drugs, isoniazid and rifampin (MDR isolates), are common. However, the number of resistant isolates 
has slowly increased. In 1991 the proportion of M. tuberculosis isolates resistant to any first-line TB drug 
(any resistance) was 2.0%, whereas in 2010 it was 7.5%. MDR isolates have been reported in 0-6 cases (0-
2.4% from all isolates) yearly. The majority of MDR isolates have been reported from foreign-born patients, 
reflecting the situation of increased immigration from high-incidence TB countries to Finland. Resistance 
to second-line TB drugs is still rare, and no XDR isolates were reported in Finland during the years 1991-
2010 (Marttila, Vasankari). 
All M. tuberculosis strains isolated in Finland are submitted to the Mycobacterial Reference Laboratory 
at the National Institute for Health and Welfare (THL). The drug susceptibility testing has been performed 
with the agar proportion method or with the MD Bactec MGIT 960 method, according to the 
recommendations of the WHO. 
 
 
Figure 4.3: Antimicrobial resistance of Mycobacterium tuberculosis isolates in Finland in 1991-2010. 
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Appendix 2. SIR antimicrobial breakpoints used in the report 
MIC breakpoint 
(mg/L) 
Disk 
content 
Zone diameter 
breakpoint (mm) 
Bacterium Abbreviation 
S ≤ R > (µg) S ≥ R < 
S. pneumoniae Penicillin (PEN) 0,064 2 10 6 0 
  Erytromycin (ERY) 0,25 1 15 21 15 
  Klindamycin (CLI) 0,25 1 2 19 15 
  Tetracycline (TCY) 2 8 30 23 18 
  Trimethoprim-Sulfa (SXT) 0,5 4 1-2 19 15 
H. influenzae Ampicillin (AMP) 1 4 10 17 13 
  Amoxicillin-clavulanic acid (AMC) 4 8 2 17 13 
  Tetracykline (TCY) 2 8 30 29 25 
  Trimethoprim-Sulfa (SXT) 0,5 4 1-2 16 10 
M. catarrhalis Ampicillin (AMP) 8 32 10 17 13 
  Amoxicillin-clavulanic acid (AMC) 8 32 20 18 13 
  Erytromycin (ERY) 0,5 8 15 23 13 
  Tetracycline (TCY) 4 16 30 19 14 
  Trimethoprim-Sulfa (SXT) 2 4 1-2 16 10 
S. pyogenes Erytromycin (ERY) 0,25 1 15 21 15 
  Klindamycin (CLI) 0,25 1 2 19 15 
E. coli Ampicillin (AMP) 8 32 10 17 13 
K. pneumoniae Piperacillin-tazobactam  (TZP) 16 128 100 21 17 
Acinetobacter spp. Cefalothine (CEP) 8 32 30 18 14 
  Cefuroxime (CXM) 8 32 30 18 14 
  Cefotaxime (CTX) 8 64 30 23 14 
  Ceftriaxone (CRO) 8 64 30 21 13 
  Ceftazidime (CAZ) 8 32 30 18 14 
  Imipenem (IPM) 4 16 10 16 13 
  Meropenem (MEM) 4 16 10 16 13 
  Tobramycin (TOB) 4 16 10 15 12 
  Netilmicin (NET) 8 32 30 15 12 
  Norfloxacin (NOR) 4 16 10 17 12 
  Ciprofloxacin  (CIP) 1 4 5 21 15 
  Levofloxacin (LVX) 2 8 5 17 13 
  Trimethoprim-Sulfa (SXT) 2 4 1-2 16 10 
  Mecillinam (MEC) 8 32 10 15 11 
  Nitrofurantoin (NIT) 32 128 300 17 14 
  Trimethoprim (TMP) 8 16 5 16 10 
P. aeruginosa Piperacillin-tazobactam  (TZP) 64 128 100 18 17 
  Ceftazidime (CAZ) 8 32 30 18 14 
  Imipenem (IPM) 4 16 10 16 13 
  Meropenem (MEM) 4 16 10 16 13 
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  Tobramycin (TOB) 4 16 10 15 12 
  Ciprofloxacin  (CIP) 1 4 5 21 15 
S. aureus Oxacillin (OXA) 2 4 1 13 10 
  Erytromycin (ERY) 0,5 8 15 23 13 
  Klindamycin (CLI) 0,5 4 2 21 14 
  Tetracycline (TCY) 4 16 30 19 14 
  Trimethoprim-Sulfa (SXT) 2 4 1-2 16 10 
  Tobramycin (TOB) 4 16 10 15 12 
  Netilmicin (NET) 8 32 30 15 12 
  Vankomycin (VAN) 2 16 30 15 0 
  Rifampicin (RIF) 1 4 5 20 16 
  Fusidic acid (FUS) 0,5 2 - - - 
Enterococcus spp. Ampicillin (AMP) 8 16 10 17 16 
  Vankomycin (VAN) 4 32 30 17 14 
  Teicoplanin (TEC) 8 32 30 14 10 
  Nitrofurantoin (NIT) 32 128 300 17 14 
N. gonorrhoeae Ciprofloxacin  (CIP) 0,064 1 5 41 27 
  Cefotaxime (CTX) 0 0,5 30 31 0 
  Ceftriaxone (CRO) 0 0,25 30 35 0 
Salmonella spp. Ciprofloxacin  (CIP) 0,125 4 5 21 15 
  Nalidixic acid (NAL) 16 32 30 19 13 
 
 
 
